Your browser doesn't support javascript.
loading
Functional CRISPR screening identifies the ufmylation pathway as a regulator of SQSTM1/p62.
DeJesus, Rowena; Moretti, Francesca; McAllister, Gregory; Wang, Zuncai; Bergman, Phil; Liu, Shanming; Frias, Elizabeth; Alford, John; Reece-Hoyes, John S; Lindeman, Alicia; Kelliher, Jennifer; Russ, Carsten; Knehr, Judith; Carbone, Walter; Beibel, Martin; Roma, Guglielmo; Ng, Aylwin; Tallarico, John A; Porter, Jeffery A; Xavier, Ramnik J; Mickanin, Craig; Murphy, Leon O; Hoffman, Gregory R; Nyfeler, Beat.
Afiliación
  • DeJesus R; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, United States.
  • Moretti F; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • McAllister G; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, United States.
  • Wang Z; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, United States.
  • Bergman P; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, United States.
  • Liu S; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, United States.
  • Frias E; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, United States.
  • Alford J; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, United States.
  • Reece-Hoyes JS; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, United States.
  • Lindeman A; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, United States.
  • Kelliher J; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, United States.
  • Russ C; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, United States.
  • Knehr J; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Carbone W; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Beibel M; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Roma G; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Ng A; Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Harvard Medical School, Boston, United States.
  • Tallarico JA; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, United States.
  • Porter JA; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, United States.
  • Xavier RJ; Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Harvard Medical School, Boston, United States.
  • Mickanin C; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, United States.
  • Murphy LO; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, United States.
  • Hoffman GR; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, United States.
  • Nyfeler B; Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Elife ; 52016 06 28.
Article en En | MEDLINE | ID: mdl-27351204
ABSTRACT
SQSTM1 is an adaptor protein that integrates multiple cellular signaling pathways and whose expression is tightly regulated at the transcriptional and post-translational level. Here, we describe a forward genetic screening paradigm exploiting CRISPR-mediated genome editing coupled to a cell selection step by FACS to identify regulators of SQSTM1. Through systematic comparison of pooled libraries, we show that CRISPR is superior to RNAi in identifying known SQSTM1 modulators. A genome-wide CRISPR screen exposed MTOR signalling and the entire macroautophagy machinery as key regulators of SQSTM1 and identified several novel modulators including HNRNPM, SLC39A14, SRRD, PGK1 and the ufmylation cascade. We show that ufmylation regulates SQSTM1 by eliciting a cell type-specific ER stress response which induces SQSTM1 expression and results in its accumulation in the cytosol. This study validates pooled CRISPR screening as a powerful method to map the repertoire of cellular pathways that regulate the fate of an individual target protein.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteínas / Procesamiento Proteico-Postraduccional / Regulación de la Expresión Génica / Proteína Sequestosoma-1 Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Humans Idioma: En Año: 2016 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteínas / Procesamiento Proteico-Postraduccional / Regulación de la Expresión Génica / Proteína Sequestosoma-1 Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Humans Idioma: En Año: 2016 Tipo del documento: Article